Development and validation of a sensitive LC‐MS/MS method with electrospray ionization for quantitation of zafirlukast, a selective leukotriene antagonist in human plasma: application to a clinical pharmacokinetic study
Authors:
- 6 February 2008
- journal article
- research article
- Published by Wiley in Biomedical Chromatography
- Vol. 22 (6) , 645-653
Abstract
A highly sensitive and specific LC‐MS/MS method has been developed and validated for the estimation of zafirlukast (ZFK) with 500 µL human plasma using valdecoxib as an internal standard (IS). The API‐4000 LC‐MS/MS was operated under multiple reaction‐monitoring mode using the electrospray ionization technique. The assay procedure involved extraction of ZFK and IS from human plasma with ethyl acetate. The resolution of peaks was achieved with 10 mm ammonium acetate (pH 6.4):acetonitrile (20:80, v/v) on a Hypersil BDS C18 column. The total chromatographic run time was 2.0 min and the elution of ZFK and IS occurred at approximately 1.11 and 1.58 min, respectively. The MS/MS ion transitions monitored were 574.2 → 462.1 for ZFK and 313.3 → 118.1 for IS. The method was proved to be accurate and precise at a linearity range of 0.15–600 ng/mL with a correlation coefficient (r) of ≥0.999. The method was rugged with 0.15 ng/mL as lower limit of quantitation. The intra‐ and inter‐day precision and accuracy values were found to be within the assay variability limits as per the FDA guidelines. The developed assay method was applied to a pharmacokinetic study in human volunteers following oral administration of 20 mg ZFK tablet. Copyright © 2008 John Wiley & Sons, Ltd.Keywords
This publication has 9 references indexed in Scilit:
- Optimisation, validation and application of a capillary electrophoretic method for the determination of zafirlukast in pharmaceutical formulationsJournal of Pharmaceutical and Biomedical Analysis, 2007
- A Reversed-Phase High-Performance Liquid Chromatographic Method for the Determination of Zafirlukast in Pharmaceutical Formulations and Human PlasmaJournal of AOAC INTERNATIONAL, 2006
- Matrix effect in bio-analysis of illicit drugs with LC-MS/MS: Influence of ionization type, sample preparation, and biofluidJournal of the American Society for Mass Spectrometry, 2003
- Determination of zafirlukast by stability indicating LC and derivative spectrophotometryJournal of Pharmaceutical and Biomedical Analysis, 2002
- Pharmacokinetic Profile of ZafirlukastClinical Pharmacokinetics, 2002
- Validation of a LC method for the analysis of zafirlukast in a pharmaceutical formulationJournal of Pharmaceutical and Biomedical Analysis, 2000
- Comparison of Zafirlukast (Accolate®) Absorption After Oral and Colonic Administration in HumansPharmaceutical Research, 2000
- The SFSTP guide on the validation of chromatographic methods for drug bioanalysis: from the Washington Conference to the laboratoryAnalytica Chimica Acta, 1999
- Determination of zafirlukast, a selective leukotriene antagonist, human plasma by normal-phase high-performance liquid chromatography with fluorescence detectionJournal of Chromatography B: Biomedical Sciences and Applications, 1997